Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody designed to specifically target the insulin-like growth factor 1 receptor (IGF-1R). This antibody functions by inhibiting the signaling pathways initiated by IGF-1 and IGF-2, which are commonly implicated in tumor cell proliferation. It effectively blocks IGF-1R autophosphorylation and subsequent phosphorylation of Akt, a critical node in the pro-survival signaling network. Additionally, Dalotuzumab promotes apoptosis and induces cell cycle arrest, further inhibiting cancer cell growth. Research has demonstrated that when used in conjunction with other anticancer agents, including statins, Dalotuzumab exhibits enhanced antitumor efficacy both in vitro and in vivo. This makes it a valuable tool for studies focused on cancer biology and therapeutic antibody development.
Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody designed to specifically target the insulin-like growth factor 1 receptor (IGF-1R). This antibody functions by inhibiting the signaling pathways initiated by IGF-1 and IGF-2, which are commonly implicated in tumor cell proliferation. It effectively blocks IGF-1R autophosphorylation and subsequent phosphorylation of Akt, a critical node in the pro-survival signaling network. Additionally, Dalotuzumab promotes apoptosis and induces cell cycle arrest, further inhibiting cancer cell growth. Research has demonstrated that when used in conjunction with other anticancer agents, including statins, Dalotuzumab exhibits enhanced antitumor efficacy both in vitro and in vivo. This makes it a valuable tool for studies focused on cancer biology and therapeutic antibody development.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
